Market Size of Androgen Deprivation Therapy Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.20 % |
| Fastest Growing Market | North America |
| Largest Market | Asia-Pacific |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Androgen Deprivation Therapy Market Analysis
The Androgen Deprivation Therapy Market is expected to register a significant CAGR of 5.2% during the study period.
The COVID-19 pandemic significantly impacted the androgen deprivation therapy market, as cancer patients, especially prostate cancer patients, were more susceptible to coronavirus than individuals without cancer. The high susceptibility was due to the immunosuppressive state caused by malignancy and anticancer treatment. Moreover, according to the data from Cancer Treatment and Research Communications published in January 2022, it was found that during the first COVID-19 wave, there was a 17% decrease in prostate cancer diagnoses in the Netherlands. The reduction was most noticeable among older people and those with low-risk localized cancer. With the decrease in the diagnosis of cancers, the use of androgen deprivation therapy (ADT) was hampered. However, the market reached its pre-pandemic nature regarding the utilization of ADT among cancer patients, which is believed to boost the market growth in the coming years.
The key factors propelling the market growth are the rising burden of prostate cancer, increasing research and development activities, advancements in treatment technology for effective treatment of prostate cancer, rising product approvals, and strategic initiatives adopted by key market players.
Strategies such as partnerships, distribution agreements, mergers, and acquisitions adopted by key market players are expected to boost market growth. For instance, in May 2022, Myovant Sciences and Accord Healthcare, Ltd. entered into an exclusive license agreement for Accord to commercialize Relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX (Relugolix, 120 mg) in the European Economic Area, United Kingdom, Switzerland, and Turkey. Such partnerships will expand the accessibility of ORGOVYX across geographies, thereby leading to lucrative market growth.
Furthermore, achieving milestones in the drug development cycle will also fuel market growth. For instance, in May 2022, Bayer reported that the United States Food and Drug Administration (FDA) had accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC).
Therefore, owing to the factors above, the studied market is expected to grow significantly during the study period. However, limited reimbursement policies and increasing side effects are expected to hinder the market growth during the study period.
Androgen Deprivation Therapy Industry Segmentation
As per the scope of the report, androgen deprivation therapy is hormone therapy for prostate cancer in males by suppressing excess androgen. Androgen is a sex hormone produced in the testes and adrenalin glands in the form of testosterone and dihydrotestosterone. The Androgen Deprivation Therapy Market is segmented by treatment (drug class (Luteinizing Hormone-Releasing Hormone (LHRH) agonists and antiandrogens) and surgery), route of administration (injectable and oral), and geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Treatment | ||||
| ||||
| By Surgery |
| By Route of Administration | |
| Injectable | |
| Oral |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Androgen Deprivation Therapy Market Size Summary
The androgen deprivation therapy market is poised for significant growth, driven by the increasing prevalence of prostate cancer and advancements in treatment technologies. The market experienced disruptions due to the COVID-19 pandemic, which affected cancer diagnoses and treatment utilization. However, it has rebounded to pre-pandemic levels, with factors such as rising prostate cancer cases, enhanced research and development activities, and strategic initiatives by key players fueling its expansion. Partnerships, product approvals, and technological advancements in treatment methods are expected to further propel market growth. Notable collaborations, such as those involving Myovant Sciences and Accord Healthcare, have expanded the accessibility of treatments like ORGOVYX, contributing to the market's positive trajectory.
In North America, particularly the United States, the androgen deprivation therapy market is expected to thrive due to the high incidence of prostate cancer and a growing elderly population. The region's market growth is supported by regulatory approvals and research demonstrating the efficacy of androgen receptor inhibitors. Key players, including Johnson & Johnson, AstraZeneca, and Bayer AG, are actively engaging in mergers, acquisitions, and partnerships to strengthen their market positions. The competitive landscape is characterized by moderate competition, with major companies driving innovation and expanding their product offerings. Overall, the market is anticipated to experience robust growth, supported by a combination of strategic initiatives and favorable demographic trends.
Androgen Deprivation Therapy Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Burden of Prostrate Cancer
-
1.2.2 Rising Research and Development Activities
-
-
1.3 Market Restraints
-
1.3.1 Poor Reimbursement and Increasing Side Effects
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - in USD)
-
2.1 By Treatment
-
2.1.1 By Drug Class
-
2.1.1.1 Luteinizing Hormone-Releasing Hormone (LHRH) agonists
-
2.1.1.2 Antiandrogens
-
-
2.1.2 By Surgery
-
-
2.2 By Route of Administration
-
2.2.1 Injectable
-
2.2.2 Oral
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Androgen Deprivation Therapy Market Size FAQs
What is the current Global Androgen Deprivation Therapy Market size?
The Global Androgen Deprivation Therapy Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)
Who are the key players in Global Androgen Deprivation Therapy Market?
Johnson and Johnson, Astrazeneca, Bayer AG, Astellas Pharma Inc. and Tolmar Pharmaceuticals, Inc. are the major companies operating in the Global Androgen Deprivation Therapy Market.
